Genetics Institute, Inc.

Dyax Corporation

Wyeth

Dana-farber-cancer Institute Inc.

Medimmune Limited

Other

Syntonix Pharmaceuticals, Inc.

Johns Hopkins University

The United States of America, As Represented by the Secretary, Department of Health and Human Services

The Brigham and Women's Hospital, Inc.

Biogen Hemophilia Inc.

The Government of the United States of America

Clive R Wood

Mary Collins

Debra D Donaldson

Matthew James Whitters

Lori J Fitz

Tamlyn Neben

Daniel T Dransfield

Gordon James Freeman

Robert Charles Ladner

Laetitia Devy

Rene Hoet

Henk Pieters

Beatriz M Carreno

Aaron Sato

Alan J Bitonti

Kevin McDonnell

Jennifer A Dumont

Christopher TenHoor

Caroline S Russell

Randal J Kaufman

Arumugam Muruganandam

Maria Henderikx

Deborah P Luxenberg

Laura L Carter

John Edward Andrews

Liming Liu

Jason Jussif

Frances K Bennett

Malini Viswanathan

Simon E Hufton

Viia Valge-Archer

Tatyana Chernova

Nelly Malenkovich

Thomas A Wynn

Marsha Wills-Karp

James Stattel

Divya Chaudhary

Monica G Chiaramonte

Irene Chernova

Gordon Freeman

Naoya Tsurushita

Arlene Helen Sharpe

Gary S Gray

Samuel Goldman

Paul Robert Hinton

Katherine Jane Turner

Denise M O'Hara

Yvette Latchman

Andrew J Long

James McGivney

Donna Morris

Joseph P Sypek

Lori Jo Fitz

Vila Valge-Archer

Michael Bowman

Laura K Carter

Frances Bennett

Caroline Russell

John Andrews

Lori Fitz

Matthew J Whitters

Kevin Mcdonnell

This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.

Antibodies to FeRn and uses thereof

Proteins that bind to matrix metalloproteinase 14 and methods of using such proteins are described.

Method for treating breast cancer using antibody binding to MMP-14

Fc receptor binding proteins

Provided are methods and compositions for using MMP-14 or MMP-9 binding proteins alone or in combination with other therapeutic agents to treat osteolytic disorders such as osteotropic cancer and osteoporosis.

Compositions and methods for treating osteolytic disorders comprising MMP-14 binding proteins

Provided are compositions, methods and kits for quantifying the expression and/or activity of MMP-14 and other biomarkers of cancer, which may be used diagnostically and prognostically, e.g., in patient stratification and evaluation of appropriate therapeutic regimens.

Evaluating MMP expression in patient stratification and other therapeutic, diagnostic and prognostic methods for cancer

Metalloproteinase binding proteins

This disclosure provides antibodies and antigen-binding fragments that can act as agonists and/or antagonists of PD-1 (Programmed Death 1), thereby modulating immune responses in general, and those mediated by TcR and CD28, in particular. The disclosed compositions and methods may be used for example, in treating autoimmune diseases, inflammatory disorders, allergies, transplant rejection, cancer, and other immune system disorders.

Nucleic acids encoding antibodies against PD-1

Tie1 and Tie2 are receptor tyrosine kinase proteins that include a transmembrane domain. Tie1 and Tie2 are present on endothelial cells. This disclosure describes agents, such as antibodies, that bind to Tie1, Tie2, and Ang, including ones that inhibit endothelial cell activity.

Antibodies to Tie1 ectodomain

Antibodies that bind MMP-14

The invention provides isolated nucleic acids molecules, designated PD-L2 nucleic acid molecules, which encode novel B7-related molecules which are ligands for PD-1. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PD-L2 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PD-L2 gene has been introduced or disrupted. The invention further provides isolated PD-L2 polypeptides, fusion proteins, antigenic peptides and anti-PD-L2 antibodies. The invention still further provides methods for promoting or inhibiting the interaction between PD-L2 and PD-1. Diagnostic and treatment methods utilizing compositions of the invention are also provided.

Methods for upregulating an immune response with agents that inhibit the intereaction between PD-L2 and PD-1

Disclosed are screening assays for identifying compounds which modulate the activity of, or signaling via, B7-4, or PD-1, especially which modulate the binding of B7-4 or PD-1 to a target molecule.

Methods for screening for compounds that modulate PD-1 signaling

Polynucleotides encoding the IL-13 receptor and fragments thereof are disclosed. IL-13 receptor proteins, methods for their production, inhibitors of binding of IL-13 and its receptor and methods for their identification are also disclosed.

Methods of using antibodies to human IL-13bc for inhibiting IL-13 binding

The invention identifies PD-1 as a receptor for B7-4. B7-4 can inhibit immune cell activation upon binding to an inhibitory receptor on an immune cell. Accordingly, the invention provides agents for modulating PD-1, B7-4, and the interaction between B7-4 and PD-1 in order to modulate a costimulatory or an inhibitory signal in a immune cell resulting in modulation of the immune response.

Methods of upmodulating an immune response with non-activating forms of B7-4

Growing community of inventors

Cambridge, MA, United States of America

Clive R Wood